Many of these industries have recently been valued at their lowest forward P/E in at least 22 years.
News & Analysis: Alexion Pharmaceuticals
Pegcetacoplan is the first drug to beat Soliris in improving hemoglobin levels in PNH patients.
These large-cap growth and value stocks could make you richer this year.
Both of these drugmakers have solid portfolios and treatment pipelines, but savvy investors will find good reason to favor one over the other.
These health-related businesses managed to surprise themselves.
ALXN earnings call for the period ending September 30, 2019.
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
The clinical-stage biotech made a new friend.
It was a roller coaster of a month for the biotech.
Why American Outdoor Brands, Innovative Industrial Properties, and Alexion Pharmaceuticals Slumped Today
Find out what caused these very different companies all to lose ground.